1. Home
  2. RMAX vs TTRX Comparison

RMAX vs TTRX Comparison

Compare RMAX & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RE/MAX Holdings Inc.

RMAX

RE/MAX Holdings Inc.

HOLD

Current Price

$9.88

Market Cap

193.4M

Sector

Finance

ML Signal

HOLD

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

N/A

Current Price

$5.96

Market Cap

174.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RMAX
TTRX
Founded
1973
2015
Country
United States
United States
Employees
N/A
2
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
193.4M
174.9M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
RMAX
TTRX
Price
$9.88
$5.96
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$11.40
$8.00
AVG Volume (30 Days)
270.7K
55.6K
Earning Date
05-07-2026
05-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.60
N/A
Revenue
$195,929,000.00
N/A
Revenue This Year
$2.62
N/A
Revenue Next Year
$1.24
N/A
P/E Ratio
$16.32
N/A
Revenue Growth
11.13
N/A
52 Week Low
$5.46
$2.57
52 Week High
$11.62
$6.75

Technical Indicators

Market Signals
Indicator
RMAX
TTRX
Relative Strength Index (RSI) 60.78 59.14
Support Level $8.77 $4.70
Resistance Level $10.32 $6.68
Average True Range (ATR) 0.35 0.55
MACD 0.04 -0.05
Stochastic Oscillator 79.57 64.35

Price Performance

Historical Comparison
RMAX
TTRX

About RMAX RE/MAX Holdings Inc.

RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Share on Social Networks: